Anticancer Drugs Oncology Pharmacology Physiotherapy Ramucirumab

Ramucirumab (16)

In this article, we will discuss Ramucirumab (16). So, let’s get started.

Warnings (5)

Gastrointestinal Perforations
Ramucirumab is an antiangiogenic therapy that can increase the risk of gastrointestinal perforation, a potentially fatal event. Four of 570 patients (0.7%) who received Ramucirumab as a single agent in clinical trials experienced gastrointestinal perforation. In Study 2, the incidence of gastrointestinal perforations was also increased in patients that received Ramucirumab plus paclitaxel (1.2%) as compared to patients receiving placebo plus paclitaxel (0.3%). Permanently discontinue Ramucirumab in patients who experience a gastrointestinal perforation.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.